Science

antipsychotic

Endocannabinoid Degradation Enzyme Inhibitors as Potential Antipsychotics: A Medicinal Chemistry Perspective

This comprehensive study, available on PubMed Central, examines the potential of targeting endocannabinoid degradation enzyme inhibitors for the development of new antipsychotic medications. Schizophrenia and other psychotic disorders often lack effective treatments with minimal side effects, driving the need for innovative approaches. The endocannabinoid system, known for its role in Read more…

By Yana Djonua, ago
cancer

Short-Term Medical Cannabis Benefits for Palliative Cancer Patients

Recent research published under the title “Short-Term Medical Cannabis Treatment Regimens Produced Beneficial Effects among Palliative Cancer Patients” has revealed promising results regarding the use of medical cannabis among those undergoing palliative care for cancer. The study, accessible through the National Center for Biotechnology Information (NCBI), indicates significant improvements in Read more…

By Yana Djonua, ago
antipsychotics

Endocannabinoid Degradation Enzyme Inhibitors as Potential Antipsychotics: A Medicinal Chemistry Perspective

Schizophrenia and related psychotic disorders pose significant challenges in contemporary psychiatry, necessitating the exploration of novel therapeutic approaches. Recent research has turned towards the endocannabinoid system and its role in psychiatric disorders. Notably, endocannabinoid degradation enzyme inhibitors have emerged as potential antipsychotics, promising a new frontier in medicinal chemistry. The Read more…

By Yana Djonua, ago
social stress

Exploring the Emotional Landscape: CBD’s Impact on Social Stress and Support in Patients

Recent research has highlighted the significant therapeutic potential of Cannabidiol (CBD) in managing social stress and enhancing emotional support among patients. This summary delves into the comprehensive study published in the National Center for Biotechnology Information (NCBI), which investigates how CBD interacts with our mental health, particularly in the context Read more…

By Yana Djonua, ago
parkinson

Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson’s Disease

Parkinson’s disease (PD) is a progressive neurodegenerative disorder marked by the loss of dopamine-producing neurons in the brain, leading to motor and non-motor symptoms. Recent research has explored the therapeutic potential of cannabidiol (CBD), a non-psychoactive compound found in cannabis, in treating PD. A study published in the PubMed Central Read more…

By Yana Djonua, ago
arthritis

Transdermal Cannabidiol Reduces Inflammation and Pain in Arthritis

Arthritis, characterized by debilitating inflammation and chronic pain, significantly impacts the quality of life for millions globally. Recent research has highlighted a promising therapeutic approach using transdermal cannabidiol (CBD). In a study published by NCBI, the efficacy of transdermal CBD in reducing inflammation and pain-related behaviors associated with arthritis was Read more…

By Yana Djonua, ago
Anandamide

Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia

Cannabidiol (CBD), a non-psychoactive compound found in cannabis, has garnered significant attention due to its potential therapeutic effects across a variety of conditions. One of the critical pathways through which CBD exerts these effects is by enhancing anandamide signaling within the endocannabinoid system (ECS). The ECS is a complex cell-signaling Read more…

By Yana Djonua, ago